WallStSmart

Dynavax Technologies Corporation (DVAX)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 5139% more annual revenue ($17.32B vs $330.51M). TEVA leads profitability with a 4.1% profit margin vs -0.1%. TEVA earns a higher WallStSmart Score of 49/100 (D+).

DVAX

Hold

45

out of 100

Grade: D+

Growth: 3.3Profit: 3.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.98

TEVA

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.5Value: 5.0Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVAX0 strengths · Avg: 0/10

No standout strengths identified

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.968/10

Growing faster than its price suggests

Areas to Watch

DVAX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

EPS GrowthGrowth
0.7%4/10

0.7% earnings growth

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.2%3/10

Operating margin of 0.2%

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
58.4x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVAX

DVAX has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.

Bear Case : DVAX

The primary concerns for DVAX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 58.4x leaves little room for execution misses. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

DVAX profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

DVAX carries more volatility with a beta of 0.93 — expect wider price swings.

DVAX is growing revenue faster at 0.2% — sustainability is the question.

DVAX generates stronger free cash flow (33M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (49/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dynavax Technologies Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?